Vanda Pharmaceuticals Files 8-K
Ticker: VNDA · Form: 8-K · Filed: May 24, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Vanda Pharma filed an 8-K, check for updates.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on May 24, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures, but it confirms the company's reporting status.
Why It Matters
This filing indicates that Vanda Pharmaceuticals is making a regulatory disclosure, which could contain important updates for investors regarding company events or financial health.
Risk Assessment
Risk Level: low — This is a routine filing and does not contain specific negative or positive news.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- May 24, 2024 (date) — Date of Report
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' are being reported, but the specific details of these events are not provided in the header information.
What is Vanda Pharmaceuticals Inc.'s principal executive office address?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 24, 2024.
What is Vanda Pharmaceuticals Inc.'s IRS Employer Identification Number?
Vanda Pharmaceuticals Inc.'s IRS Employer Identification Number is 03-0491827.
What is the Standard Industrial Classification code for Vanda Pharmaceuticals Inc.?
The Standard Industrial Classification code for Vanda Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-24 16:49:41
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20240524.htm (8-K) — 32KB
- vnda8-k5242024exhibit991.htm (EX-99.1) — 9KB
- vandaq32019earningsca_imaga.jpg (GRAPHIC) — 48KB
- 0001628280-24-025254.txt ( ) — 277KB
- vnda-20240524.xsd (EX-101.SCH) — 3KB
- vnda-20240524_def.xml (EX-101.DEF) — 16KB
- vnda-20240524_lab.xml (EX-101.LAB) — 28KB
- vnda-20240524_pre.xml (EX-101.PRE) — 16KB
- vnda-20240524_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On May 24, 2024, Vanda Pharmaceuticals Inc. ("Vanda"), a Delaware corporation, issued a press release announcing that its Board of Directors, in consultation with its independent financial and legal advisors, and consistent with its fiduciary duties, rejected a revised, unsolicited acquisition proposal from Future Pak, LLC. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated May 24 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 24, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary